Aims: Adventitial remodelling presenting with the phenotypic switch of adventitial fibroblasts (AFs) to myofibroblasts is reportedly involved in the evolution of several vascular diseases, including hypertension. In our previous study, we reported that heat shock protein 90 (HSP90) inhibition by 17-dime-thylaminoethylamino-17-demethoxygeldanamycin (17-DMAG) markedly attenuates angiotensin II (AngII)-induced abdominal aortic aneurysm formation by simultaneously inhibiting several key signalling and transcriptional pathways in vascular smooth muscle cells; however, little is known about its role on AFs. Given that the AF phenotypic switch is likely to be associated with mitochondrial function and calcineurin (CN), a client protein of HSP90 that mediates mitochondrial fission and function, the aim of this study was to investigate whether mitochondrial fission contributes to phenotypic switch of AF, and if it does, we further aimed to determine whether HSP90 inhibition attenuates mitochondrial fission and subsequently suppresses AF transformation and adventitial remodelling in AngII-induced hypertensive mice. Methods and results: In primary mouse AFs, we found that CN-dependent dephosphorylation of Drp1 induced mitochondrial fission and regulated mitochondrial reactive oxygen species production, which stimulated AF proliferation, migration, and phenotypic switching in AngII-treated AFs. Moreover, AngII was found to increase the binding of HSP90 and CN in AFs, while HSP90 inhibition significantly reversed AngII-induced mitochondrial fission and AF phenotypic switching by modulating the CN-dependent dephosphorylation of Drp1. Consistent with the effects in AFs, in an animal model of AngII-induced adventitial remodelling, 17-DMAG markedly reduced mitochondrial fission, AF differentiation, vessel wall thickening, and fibrosis in the aortic adventitia, which were mediated by CN/Drp1 signalling pathways. Conclusions: Our study suggests that CN/Drp1-dependent mitochondrial fission may be essential for understanding adventitial remodelling in hypertension and that HSP90 inhibition may serve as a novel approach for the treatment of adventitial remodelling-related diseases.
1 January 2018 in Evidence-Based Complementary and Alternative Medicine
Loganin, iridoid glycosides, is the main bioactive ingredients in the plant Strychnos nux-vomica L. and demonstrates various pharmacological effects, though poor oral bioavailability in rats. In this study, the intestinal absorption mechanism of loganin was investigated using the human intestinal Caco‐2 cell monolayer model in both the apical‐to‐basolateral (A‐B) and the basolateral‐to‐apical (B‐A) direction; additionally, transport characteristics were systematically investigated at different concentrations, pHs, temperatures, and potential transporters. The absorption permeability (PappAB) of loganin, which ranged from 12.17 to 14.78 × 10−6cm/s, was high at four tested concentrations (5, 20, 40, and 80μM), while the major permeation mechanism of loganin was found to be passive diffusion with active efflux mediated by multidrug resistance‐associated protein (MRP) and breast cancer resistance protein (BCRP). In addition, it was found that loganin was not the substrate of efflux transporter P‐glycoprotein (P‐gp) since the selective inhibitor (verapamil) of the efflux transporter exhibited little effects on the transport of loganin in the human intestinal Caco‐2 cells. Meanwhile, transport from the apical to the basolateral side increased 2.09‐fold after addition of a MRP inhibitor and 2.32‐fold after addition of a BCRP inhibitor. In summary, our results clearly demonstrate, for the first time, a good permeability of loganin in the human intestinal Caco‐2 cell model and elucidate, in detail, the intestinal absorption mechanism and the effects of transporters on iridoid glycosides compounds.
The Gandi capsule, a famous traditional Chinese medicine (TCM), is a hospital preparation that has been widely used in China for decades for the treatment of diabetes. The aim of this study is to compare the pharmacokinetics of four of the active components of Gandi capsules, which are the primary antidiabetic ingredients, on normal and diabetic Sprague-Dawley rats following oral administration of the capsules. Baicalin, wogonoside, wogonin, loganin and puerarin (internal standard) were prepared using methanol precipitation, and the separation of the five components was achieved through a ZORBAX Eclipse Plus C18 column by gradient elution using water (containing 0.1% formic acid) and acetonitrile as the mobile phase. After oral administration of Gandi capsules to the normal and diabetic rats, plasma was harvested and analyzed using liquid chromatography coupled with tandem mass spectrometry, and the primary pharmacokinetic parameters were calculated by DAS 2.0. Compared with the normal group, some pharmacokinetic parameters especially the AUC0–48 h of the four compounds significantly increased in the diabetic groups. The results demonstrated that the four constituents in normal and diabetic rats had obvious differences in some pharmacokinetic characteristics, suggesting that the rate and extent of drug metabolism were altered in diabetic animals. The results could be helpful for demonstrating the compatibility mechanism and providing clinical medication guidance for Gandi capsules.
Morroniside is biologically active polyphenols found in Cornus officinalis Sieb. et Zucc (CO) which exhibits a broad spectrum of pharmacological activities, such as protecting nerves, preventing diabetic liver damageand renal damage. However, little data is available regarding its mechanism ofintestinal absorption. Here, ahuman intestinal epithelial cell model Caco-2 cell in vitro cultured was applied to study on the absorption and transport of morroniside, the effects of time, donor concentration,pH, temperature and inhibitors,the absorption and transport of morroniside were investigated.The bidirectional permeability of morroniside from the apical (AP) to the basolateral (BL) side and in the revese direction was studied. When administrated was setat three tested concentrations (5, 25 and 100μM), the P app value in AP-to-BL direction was ranged from 1.59 to 2.66×10 -6 cm/s. Inthe reverse direction, BL-to-AP, the value was ranged from 2.67to 4.10 ×10 -6 cm/s.The data indicated that morroniside transport was both pH- and temperature- dependent. The morroniside’s permeability process affected bytreatment with various inhibitors, such as the multidrug resistance protein inhibitors MK571 and benzbromarone, the breast cancer resistance protein inhibitor apigenin.It can be found that the mechanisms of intestinal absorption of morroniside may involve multiple transport pathways like passive diffusion as well as efflux protein-mediated active transportespecially the multidrug resistance protein2 and breast cancer resistance protein.After CO was added, P app AB increased significantly by about 125.26%, it can therefore be assumed that some ingredients in the crude material promote morroniside’s absorption in the small intestine.
17 June 2026 in Acta Poloniae Pharmaceutica - Drug Research
Background: Contrast-induced acute kidney injury (CI-AKI) and associated vascular endothelial damage represent significant clinical complications, yet effective preventive strategies remain limited. This study aims to investigate the protective efficacy of trigonelline against these injuries and elucidate its intestinal transport mechanisms to support its potential as a therapeutic agent. Methods: In this study, a contrast-induced acute kidney injury model was established in mice by tail vein injection of iohexol to investigate the kidney protective effects of trigonelline. Using a Caco-2 intestinal epithelial cell monolayer model, the transport characteristics of trigonelline and the involvement of potential transporters were systematically evaluated. Results: The concentration gradients of trigonelline used in the experiments showed no cytotoxic effects on Caco-2 cells. Trigonelline exhibited moderate intestinal absorption. The efflux transporters P-glycoprotein (P-gp) and breast cancer resistance protein (BCRP) were involved in the intestinal transport of trigonelline. Crucially, in the in vivo mouse model, trigonelline treatment significantly ameliorated iohexol-induced renal injury, evidenced by a dose-dependent reduction in serum creatinine and BUN levels, and a decrease in inflammatory cytokines (IL-6, TNF-α). Histopathological analysis confirmed that trigonelline effectively mitigated renal tubular necrosis and interstitial inflammation. Conclusion: The transport characteristics and potential vascular protective effects of trigonelline provide valuable insights for the design and development of therapeutic agents aimed at preventing contrast agent-induced vascular injury, and also contribute to a deeper understanding of the pharmacological activity of trigonelline.